Drug Profile


Alternative Names: SC 36602

Latest Information Update: 23 Jun 1995

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Class I antiarrhythmics
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 23 Jun 1995 Discontinued-II for Arrhythmias in USA (Parenteral)
  • 08 Dec 1994 Phase-I clinical trials for Arrhythmias in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top